Clinical Trial Update: Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function [Phase 3]

View source ↗

Summary

Phase 3 study comparing PRX-102 to Agalsidase Beta in Fabry disease completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• PRX-102
• agalsidase beta (agalsidase beta)

Snippet

Sponsor: Protalix | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-08-02